Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

Basit Öğe Kaydı
dc.authoridbeypınar, İsmail/0000-0002-0853-4096
dc.authoridTurker, Sema/0000-0001-9040-7266
dc.authoridTanriverdi, Ozgur/0000-0002-0598-7284
dc.authoridPaydas, Semra/0000-0003-4642-3693
dc.authorscopusid6603166584
dc.authorscopusid7006287366
dc.authorscopusid56304997100
dc.authorscopusid57387529400
dc.authorscopusid57211777547
dc.authorscopusid57204682729
dc.authorscopusid23018424300
dc.authorwosidbeypınar, İsmail/AAN-1107-2020
dc.authorwosidDOGAN, MUTLU/GNP-7311-2022
dc.authorwosidTanriverdi, Ozgur/M-2172-2015
dc.authorwosidTurker, Sema/ABE-5926-2021
dc.authorwosidPaydas, Semra/F-3132-2018
dc.contributor.authorBilici, Ahmet
dc.contributor.authorUysal, Mukremin
dc.contributor.authorMenekse, Serkan
dc.contributor.authorAkin, Semih
dc.contributor.authorYildiz, Fatih
dc.contributor.authorTuran, Merve
dc.contributor.authorSezgin Goksu, Sema
dc.date.accessioned2023-01-12T19:59:22Z
dc.date.available2023-01-12T19:59:22Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractPurpose This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (MBC) patients in real-life settings. Methods Overall, 204 HR+, HER2- MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). Conclusion We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER - MBC patients.en_US
dc.identifier.doi10.1080/07357907.2021.2017952
dc.identifier.endpage209en_US
dc.identifier.issn0735-7907
dc.identifier.issn1532-4192
dc.identifier.issue2en_US
dc.identifier.pmid34894960en_US
dc.identifier.scopus2-s2.0-85121803055en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage199en_US
dc.identifier.urihttps://doi.org/10.1080/07357907.2021.2017952
dc.identifier.urihttps://hdl.handle.net/11454/77155
dc.identifier.volume40en_US
dc.identifier.wosWOS:000734258300001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofCancer Investigationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEverolimusen_US
dc.subjectexemestaneen_US
dc.subjectmetastatic breast canceren_US
dc.subjecthormone receptor-positiveen_US
dc.subjectHER - negativeen_US
dc.subjectefficacyen_US
dc.subjectAromatase Inhibitorsen_US
dc.subjectSurvivalen_US
dc.subjectMtoren_US
dc.subjectHr+en_US
dc.subjectChemotherapyen_US
dc.subjectSensitivityen_US
dc.subjectCombinationen_US
dc.subjectGuidelinesen_US
dc.subjectResistanceen_US
dc.subjectTherapiesen_US
dc.titleReal-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu